The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing artemisinin derivative (artemisinin-based combination therapies also known as ACTs). All of the following combination therapies are recommended if such resistance is suspected, except :
Artemether plus lumefantrine
Artesunate plus quinine
Artesunate plus pyrimethamine-sulfadoxine
Artesunate plus mefloquine